Get the Daily Brief
Latest Biotech News
AstraZeneca Pledges $50 Billion US Investment Amid Tariff Concerns
AstraZeneca has committed $50 billion over the next five years to manufacturing and R&D projects across the United States, including a new drug factory in Virginia, its largest to date. This...
Replimune Cancer Therapy Faces FDA Setback, Shares Plummet
Replimune Group’s oncolytic virus therapy RP1, intended for advanced melanoma treatment, received a complete response letter from the FDA citing inadequate trial design and heterogeneity of...
Sarepta pauses Duchenne therapy shipments amid FDA safety dispute
Sarepta Therapeutics has voluntarily and temporarily halted shipments of its Duchenne muscular dystrophy gene therapy Elevidys in the US following safety concerns linked to patient deaths and...
Sanofi acquires Vicebio to expand respiratory vaccine portfolio
Sanofi has agreed to acquire London-based biotech Vicebio in a deal valued at $1.15 billion upfront with potential milestone payments of $450 million, aiming to broaden its respiratory vaccine...
Replimune’s oncolytic virus melanoma therapy rejected by FDA
The FDA issued a complete response letter rejecting Replimune Group’s Biologics License Application for RP1, an oncolytic virus therapy combined with nivolumab for advanced melanoma. The agency...
Abivax ulcerative colitis drug shows strong Phase 3 results amid funding pressures
French biotech Abivax’s oral drug obefazimod demonstrated statistically significant clinical remission rates in twin Phase 3 trials for moderate to severe ulcerative colitis, surpassing previous...
Automation and AI-driven advances in biomanufacturing and mRNA production
Emerging innovations in biomanufacturing are leveraging automation, AI, and advanced modeling to streamline processes and reduce costs. Notably, new mathematical models for in vitro transcription...
AstraZeneca commits $50 billion to US manufacturing and R&D expansion
AstraZeneca announced a $50 billion investment plan to expand its U.S. manufacturing and research infrastructure through 2030, including the largest facility it has ever built in Virginia focused...
Cancer immunotherapy innovations and biotech fundraising
The cancer immunotherapy sector sees emerging approaches and substantial funding rounds aiming to tackle solid tumors. Dispatch Bio, a startup backed by $216 million from investors including the...
Biotech industry earnings and market outlook for CDMOs and diagnostics
Contract development and manufacturing organizations (CDMOs) including Lonza, Thermo Fisher, and Samsung Biologics reported earnings exceeding expectations despite client funding challenges and...
Breakthrough cancer and neurodegenerative research advances
Novel research highlights promising therapeutic strategies across oncology and neurology. Identification of autoantibodies influencing immunotherapy response offers a route to improved cancer...
Genomic and bioinformatics innovations enhance precision medicine
Advances in human genome sequencing reveal complex gene duplications linked to brain function and evolutionary traits. Bioinformatics collaborations, such as between TileDB and Databricks,...
Innovations in RNA technology and therapeutic development
Orbital Therapeutics’ next-generation circular RNA technology advances in vivo CAR-T cell therapy development, potentially offering improved delivery and gene expression profiles. Concurrently,...
Thermo Fisher Posts Q2 Beat, Sets Leadership Transition
Thermo Fisher Scientific reported a 3% year-over-year revenue increase to $10.86 billion in Q2, surpassing analyst estimates with a 6% rise in life sciences solutions revenue. Net income reached...
Sarepta's Duchenne Gene Therapy Hits Regulatory Roadblocks
Sarepta Therapeutics faced significant setbacks as the FDA demanded a halt of its Duchenne muscular dystrophy gene therapy Elevidys amid safety concerns following multiple patient deaths due to...
Sanofi Expands Respiratory Vaccine Pipeline with Vicebio Acquisition
Sanofi announced a $1.15 billion upfront acquisition of London-based biotech Vicebio, gaining an early-stage vaccine candidate targeting RSV and human metapneumovirus. The deal includes potential...
Dispatch Bio Launches with $216M to Target Solid Tumors via Novel CAR-T
Dispatch Bio debuted with $216 million in funding to develop a universal immunotherapy for solid tumors. The approach uses a dual mechanism with a viral vector tagging cancer cells and CAR-T or...
Abivax’s Ulcerative Colitis Drug Posts Dual Phase 3 Successes
French biotech Abivax reported positive results from two Phase 3 trials of its oral treatment obefazimod for moderate to severe ulcerative colitis. The pooled clinical remission rate was 16.4%...
AstraZeneca Commits $50B to U.S. Manufacturing and R&D Expansion
AstraZeneca announced plans to invest $50 billion in the U.S. over the next five years for manufacturing and research facilities, including the company’s largest-ever plant in Virginia. The...
Gene Editing Brings Hope for Rare Neurodevelopmental Disorder Treatment
Researchers utilized prime editing technology to correct five mutations responsible for alternating hemiplegia of childhood (AHC), a rare neurodevelopmental disorder. The approach demonstrated up...